

15 October 2015

rasml@tga.gov.au

**Re: Consultation: Cimetidine, famotidine, nizatidine and ranitidine for oral use:
proposed amended label advisory statements**

The Society of Hospital Pharmacists of Australia (SHPA) is the national professional organisation for over 3,000 pharmacists, pharmacists in training, pharmacy technicians and associates working across Australia's health system. SHPA is the only professional pharmacy organisation with a core base of members practising in public and private hospitals and other health service facilities.

SHPA is committed to facilitating the safe and effective use of medicines, which is the core business of pharmacists, especially in hospitals. SHPA supports pharmacists to meet medication and related service needs, so that both optimal health outcomes and economic objectives are achieved for Australians, as individuals, for the community as a whole and for healthcare facilities within our systems of healthcare.

SHPA supports the amendments to entries in the *Required Advisory Statements for Medicine Labels* for cimetidine, famotidine, nizatidine and ranitidine, to: *'This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.'*

SHPA believes that these changes should be included in the Product Information and Consumer Medicines Information (CMI) for these medicines, and that all medicine boxes should contain a CMI leaflet.

If you would like to discuss the contents of SHPA's submission or require further information, please do not hesitate to contact our office. (shpa@shpa.org.au or 03 9486 0177)

Yours sincerely,



Professor Michael Dooley
SHPA Federal President

The Society of Hospital Pharmacists of Australia

Mailing address: PO Box 1774 Collingwood 3066 Victoria Australia
Office location: Suite 3, 65 Oxford Street Collingwood 3066 Victoria Australia
T: 61 3 9486 0177 F: 61 3 9486 0311 E: shpa@shpa.org.au W: www.shpa.org.au